Dietary intake of food bioactives in a cohort of European adults with metabolic syndrome enrolled in the Pathway-27 trial

Metabolic syndrome (MetS) is the name given to a cluster of conditions that occur together more often than can be explained by chance. It is estimated that 20 – 25 % of the global adult population have MetS (1) and are three times as likely to suffer a heart attack or stroke and have a fi vefold greater risk of developing type-2 diabetes compared with people who do not have MetS (2 – 3) . The PATHWAY-27 project evaluated the effectiveness of bioactive enriched food (BEF) on improving risk factors of MetS in participants at risk, or with, MetS. Following ethical approval, the trial was registered on clinicaltrials.gov (trial # NCT02702713). The bioactive compounds selected were docosahexaenoic acid (DHA), oat beta-glucan (OBG) and grape anthocyanins (AC). In a multi-centre, randomized, double-blind, nutritional intervention trial, 251 human volunteers were recruited to consume BEF for 12 weeks. Metabolic and anthropometric markers were measured at 0, 6 and 12 weeks. Dietary exposure to DHA, OBG and AC from the participants ’ typical diet was assessed at baseline using a food frequency questionnaire. Participants were asked to estimate the frequency of consumption and portion size of foods known to contain each bioactive over 6-weeks prior to the start of the trial. Bioactive com-position information was derived from national and international databases (EuroFIR; Polyphenol Explorer), literature information and direct analysis of foods. A deterministic exposure analysis was used to calculate dietary exposure for each participant enrolled in the trial according to equation (1) where E = exposure of individual (j); n = number of portions on day (k) of food commodity (l), w = portion of food, c = concentration of bioactive.